Increase your odds in fighting cancer with Hi-Precision Diagnostic tool - test CA-62 marker of epithelial carcinomas - the successor of RecAf technology
The identifying the receptor(it's part) of alphafetoprotein (RecAf) in blood was done by Ricardo Moro nearly two decades ago. The technology is based on its ability to detect specific Cancer antigen CA-62 expressed on epithelial cancer cells. More than 5,000 samples were studied using CA-62 test with materials from cancer research centers in Europe, the USA, Canada and Russia.
The major product of the company is the diagnostic test kit based on the innovative Marker of Epithelial Carcinomas MEC, which appears on the surface of the malignant epithelial cells from the very onset of oncogenesis.
Thus, the innovativeness of the “MEC" technology and its competitive advantage over other cancer markers is that it is very effective method for early detection of the epithelial tumors. The test can be performed in combination with other registered cancer markers such as PSA, CA-125, CA-15-3, CEA or as independent screening instrument that significantly increases overall survival of the patients.
In addition to the early detection of cancer, the technology “MEC" can also be effectively used for cancer monitoring in patients with advanced cancer and for the evaluation of the treatment effectiveness, as well as for the relapse diagnosis in patients, as it was previously shown in a blind clinical study. The dynamics of the MEC biomarker’s changes during the course of chemotherapy in patients with advanced cancer of the stomach and the lung showed a good correlation (75%) with the patient’s overall response status according to the RECIST criteria. It was shown that there is a possibility of using the technology “MEC" for monitoring of the cancer disease and for assessing of an ongoing systemic treatment.
The test kit is designed for:
1) Detection of the early stages of epithelial cancer, such as breast cancer, prostate cancer, lung cancer, stomach cancer, ovarian cancer, etc.
2) Monitoring the treatment of cancer patients using the dynamics of the CA-62 marker during chemotherapy. This allows to quickly (within 1 month) identify the inefficiency of some therapy and to change the course.
Pilot clinical studies on patients with different stages of prostate cancer, breast cancer, and ovarian cancer using a new cancer marker MEC showed >90% Sensitivity with 95% Specificity of the test for early stages of cancer. Monitoring the dynamics of the cancer marker CA-62 for the patients with advanced stages of cancer during a course of chemotherapy have demonstrated a very good correlation between expression of CA-62 marker and a clinical status of the patient according to the criterion RECIST. Within the framework of this project an industrial set of reagents will be developed for cancer treatment monitoring and for early detection of cancer based on the MEC biomarker. The test system is expected to be registered in RF and abroad, as well as organization of its manufacturing
The Project Dynamics
JVS DIAGNOSTICS llc have took part in Russian Oncological CongressThe report "The possibility to use the epithelial carcinoma marker CA-62 for the early detection of malignant epithelial tumors" during Skolkovo session headed by the Academician Alexander G. Rumyantsev was done in Russian Oncological Congress by Janneta R. Tcherkassova - the JVS CEO. https://rosoncoweb.ru/events/2018/11/13/program/
JVS DIAGNOSTICS llc during the Open Innovations 2018 has declared the finalizing the first round of investments
The UCT inc Toronto, Canada has finished the first round of investments to develop its JVS Diagnostics subsidiary. This declaration was done during Open Innovations Forum and shared by media. The first press release was published by Forbes Russia. Also The Skolkovo Innovation Center has shared it's own press release.